Are weight-loss drugs sustainable? Investors grapple with ESG risks
Off-label use and pricing among concerns amid booming market for drugs made by pharma firms such as Novo Nordisk.
Off-label use and pricing among concerns amid booming market for drugs made by pharma firms such as Novo Nordisk.
Copyright PEI Media
Not for publication, email or dissemination